Now the second NGF-1 antibody, from Regeneron and Sanofi-Aventis, has been put on ice, too.

FORBES: Promising Pain Drugs Put On Ice

Even more intensely awaited are the results of a second-stage trial of Wyeth's antibody, bapineuzumab.

FORBES: Attacking Alzheimer's

Another promising treatment: an anti-CD20 antibody--kind of a second-generation Rituxan--that Genentech plans to test against rheumatoid arthritis, lupus and multiple sclerosis.

FORBES: Magazine Article

At the May cancer conference Genentech was expected to unveil second-stage trial results showing that its antibody in combination with chemotherapy delayed the growth of colon tumors for up to four months compared to chemo alone, and added months to patients' lives.

FORBES: Targeting Tumors